Scandinavian ChemoTech

Retransmission of the press release that was published, with the associated MAR label, on June 4th, 2024, at 19:00 CET.

Scandinavian ChemoTech's Animal Care operation continues to thrive, securing a new order just days after achieving a record-breaking month. This latest order, from United Veterinary Care (UVC) in Springfield of USD 46,000, brings our collective sales for the second quarter to EUR 134,000 so far, surpassing the previous record quarter (EUR 124,400).

Each month, with every installation of the vetIQure™ TSE system, we move closer to a cashflow-positive operation. United Veterinary Care is a leading, fast-growing veterinary chain in the United States, known for its primary, specialty, and emergency veterinary practices and is owned by the Swedish Private Equity group Nordic Capital.

Highlights of United Veterinary Care:

• Exceptional Veterinary Professionals: A focus on top-notch veterinary professionals and seamless support to enable practitioners to concentrate on clinical work.
• Strong Support Organization: An industry-leading support centre in Florida and long-term clinical development opportunities and training.
• Extensive Network: Over 100 veterinary practices across 20+ states in the US, with 2,000+ dedicated professionals caring for 400,000 pet patients annually.

"We are excited about ChemoTech's growing presence in the veterinary industry in both the US and Europe," said Mohan Frick, CEO of Scandinavian ChemoTech. "It's no surprise that we are on track to breaking new sales records, given the continuous reports of the clinical and financial benefits that TSE delivers to both patients and treating hospitals. We are now at a stage where we need to expand our sales force and enhance our CRM approach."

For more information about ChemoTech's Animal Care Division and the vetIQure™ TSE system, please visit www.chemotech.se or www.vetIQure.com

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Certified Adviser: Redeye AB

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.